PE20081350A1 - Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol - Google Patents

Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol

Info

Publication number
PE20081350A1
PE20081350A1 PE2007001719A PE2007001719A PE20081350A1 PE 20081350 A1 PE20081350 A1 PE 20081350A1 PE 2007001719 A PE2007001719 A PE 2007001719A PE 2007001719 A PE2007001719 A PE 2007001719A PE 20081350 A1 PE20081350 A1 PE 20081350A1
Authority
PE
Peru
Prior art keywords
alpha
beta
naphthalenyl
dimethylamine
bromo
Prior art date
Application number
PE2007001719A
Other languages
English (en)
Spanish (es)
Inventor
Jean Francois Alexandre Lucas Hegyi
Wim Albert Alex Aelterman
Yolande Lydia Lang
Sigrid Carl Maria Stokbroekx
Carina Leys
Remmoortere Peter Jozef Maria Van
Anne Faure
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37983588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081350(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20081350A1 publication Critical patent/PE20081350A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2007001719A 2006-12-05 2007-12-05 Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol PE20081350A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06125443 2006-12-05

Publications (1)

Publication Number Publication Date
PE20081350A1 true PE20081350A1 (es) 2008-09-18

Family

ID=37983588

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001719A PE20081350A1 (es) 2006-12-05 2007-12-05 Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol

Country Status (34)

Country Link
US (1) US8546428B2 (https=)
EP (1) EP2086940B1 (https=)
JP (2) JP2010511663A (https=)
KR (1) KR101514700B1 (https=)
CN (2) CN105012303A (https=)
AP (1) AP2498A (https=)
AR (1) AR064149A1 (https=)
AU (1) AU2007328945B2 (https=)
BR (1) BRPI0719693A2 (https=)
CA (1) CA2668512C (https=)
CL (1) CL2007003472A1 (https=)
CY (1) CY1113594T1 (https=)
DK (1) DK2086940T3 (https=)
EA (1) EA017091B9 (https=)
ES (1) ES2387923T3 (https=)
HK (1) HK1214513A1 (https=)
HR (1) HRP20120639T1 (https=)
IL (1) IL199077A (https=)
JO (1) JO2973B1 (https=)
ME (1) ME01456B (https=)
MX (1) MX2009005909A (https=)
MY (1) MY148844A (https=)
NO (1) NO342773B1 (https=)
NZ (1) NZ576485A (https=)
PE (1) PE20081350A1 (https=)
PL (1) PL2086940T3 (https=)
PT (1) PT2086940E (https=)
RS (1) RS52408B (https=)
SI (1) SI2086940T1 (https=)
TW (1) TWI417098B (https=)
UA (1) UA97813C2 (https=)
UY (1) UY30762A1 (https=)
WO (1) WO2008068231A1 (https=)
ZA (1) ZA200903907B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120010216A1 (en) * 2010-07-06 2012-01-12 Brown Arthur M Pharmaceutical compositions containing vanoxerine
CZ2014708A3 (cs) * 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
IL310920A (en) * 2015-01-27 2024-04-01 Janssen Pharmaceutica Nv Dispersible compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) * 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN108349898B (zh) * 2015-10-20 2021-03-23 浙江海正药业股份有限公司 富马酸贝达喹啉的晶型及其制备方法
US10710980B2 (en) * 2016-07-20 2020-07-14 Novartis Ag Aminopyridine derivatives and their use as selective ALK-2 inhibitors
CN106316943A (zh) * 2016-07-27 2017-01-11 重庆华邦制药有限公司 富马酸贝达喹啉晶型化合物的精制方法
SI3943070T1 (sl) 2017-07-14 2024-03-29 Janssen Pharmaceutica Nv, Dolgo delujoče formulacije bedakilina
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) * 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
KR102303635B1 (ko) * 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
CN117399070B (zh) * 2022-07-07 2025-06-24 上海交通大学 含有螯合配体的双手性金属协同催化体系及其不对称合成贝达喹啉的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
GB8824392D0 (en) * 1988-10-18 1988-11-23 Ciba Geigy Ag Dispersible formulation
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
WO1998018326A1 (en) 1996-10-28 1998-05-07 Department Of The Army, U.S. Government Compounds, compositions and methods for treating antibiotic-resistant infections
CZ341297A3 (cs) * 1996-10-30 1998-05-13 Eli Lilly And Company Způsob zlepšení léčby nebo profylaxe rakoviny prsu
US6819464B2 (en) * 2002-06-19 2004-11-16 Seiko Epson Corporation Optical modulator, optical device and projector
ATE463482T1 (de) * 2002-07-25 2010-04-15 Janssen Pharmaceutica Nv Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
PL1753427T3 (pl) * 2004-05-28 2008-09-30 Janssen Pharmaceutica Nv Zastosowanie podstawionych pochodnych chinoliny do leczenia chorób wywoływanych przez prątki lekooporne
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置

Also Published As

Publication number Publication date
AP2009004870A0 (en) 2009-06-30
MY148844A (en) 2013-06-14
EA017091B1 (ru) 2012-09-28
EA200970532A1 (ru) 2009-10-30
JO2973B1 (en) 2016-03-15
PT2086940E (pt) 2012-08-09
JP2010511663A (ja) 2010-04-15
DK2086940T3 (da) 2012-08-20
CA2668512C (en) 2015-03-24
ME01456B (me) 2014-04-20
WO2008068231A1 (en) 2008-06-12
EP2086940A1 (en) 2009-08-12
UA97813C2 (uk) 2012-03-26
ES2387923T3 (es) 2012-10-04
NO20092535L (no) 2009-08-06
EP2086940B1 (en) 2012-05-16
AU2007328945B2 (en) 2014-04-03
US8546428B2 (en) 2013-10-01
UY30762A1 (es) 2008-07-03
CA2668512A1 (en) 2008-06-12
CY1113594T1 (el) 2016-06-22
AP2498A (en) 2012-10-19
JP2015028049A (ja) 2015-02-12
BRPI0719693A2 (pt) 2013-12-24
KR20090087020A (ko) 2009-08-14
NZ576485A (en) 2012-01-12
PL2086940T3 (pl) 2012-10-31
AR064149A1 (es) 2009-03-18
AU2007328945A1 (en) 2008-06-12
SI2086940T1 (sl) 2012-09-28
NO342773B1 (no) 2018-08-06
TW200838527A (en) 2008-10-01
CN105012303A (zh) 2015-11-04
CN101547904A (zh) 2009-09-30
US20100028428A1 (en) 2010-02-04
EA017091B9 (ru) 2014-10-30
HK1214513A1 (zh) 2016-07-29
HRP20120639T1 (hr) 2012-08-31
KR101514700B1 (ko) 2015-04-24
JP5894239B2 (ja) 2016-03-23
TWI417098B (zh) 2013-12-01
CL2007003472A1 (es) 2008-08-22
RS52408B (sr) 2013-02-28
IL199077A (en) 2016-09-29
MX2009005909A (es) 2009-06-16
ZA200903907B (en) 2013-08-28

Similar Documents

Publication Publication Date Title
PE20081350A1 (es) Sal fumarato de (alfas s, beta r)-6-bromo-alfa-[2(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
RU2009126767A (ru) Производное 1-фенил-1-тио-d-глюцитола
BRPI0606318A2 (pt) composto, composição, e, uso de um composto
CL2009001980A1 (es) Combinacion farmaceutica que comprende un derivado de quinolina y uno o mas de otros agentes antimicobacterianos; composicion farmaceutica que la comprende; y uso para el tratamiento de una infeccion por una cepa de mycobacterium resistente a farmacos (divisional de la solicitud 1290-05).
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
AR051322A1 (es) Composiciones de amitraz
CL2008001024A1 (es) Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades cardiovasculares, parkinson, enfermedades inflamatorias, esclerosis multiple, cancer, entre otras
AR109263A2 (es) Composición que comprende moxidectina
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
AR044200A1 (es) Composicion de fondaparinux sodico de alta pureza ,un procedimiento de preparacion de esta composicion y composiciones farmaceuticas que la contienen como principio activo
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
AR029412A1 (es) Forma cristalina
AR056369A1 (es) Compuestos derivados de quinazolina y composicion farmaceutica
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
AR062393A1 (es) Uso de derivado del 2.5-dihidrixibenceno para el tratamiento de artritis y dolor
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
PE20081547A1 (es) Agentes terapeuticos que contienen un antagonista de interleucina-6 como ingrediente activo
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
BR112014031649A2 (pt) composto representado pela fórmula 1 tendo a enzima inibidora de atividade 11b-hsd1; método para sua produção e composição farmacêutica contendo o mesmo como ingrediente ativo
UY31058A1 (es) Formulaciones de aminoacido n-halogenado con compuestos antiinflamatorios
UY31059A1 (es) Formulaciones de aminoacido n-halogenado

Legal Events

Date Code Title Description
FG Grant, registration